<DOC>
	<DOCNO>NCT01309490</DOCNO>
	<brief_summary>The purpose study learn whether oral Ribavirin safe effective treating patient solid tumour cancer , high level protein eIF4E .</brief_summary>
	<brief_title>Phase I/II Study Ribavirin Given Monotherapy Solid Tumour Cancer Patients</brief_title>
	<detailed_description>This dose escalating , open-label , Phase I/II study single agent oral ribavirin administer daily solid tumour cancer patient fail standard treatment , overexpress eIF4E , easily accessible disease serial biopsy .</detailed_description>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Phase I part study : Histologically cytologically confirm cancer diagnosis , advance , incurable disease time screening , progress suitable standard therapy . Phase II part study : Histologically cytologically confirm BC HNSCC diagnosis , advance , incurable disease time screening , progress suitable standard therapy . 2 . Willing screen biopsy perform easily accessible lesion ( ex . skin , superficial lymph node ) AND whose tumour must overexpress eIF4E . 3 . Easily accessible lesion serial biopsy ( ex . skin , superficial lymph node , easily accessible site ) . 4 . At least 1 unidimensionally measurable lesion ( base RECIST criterion ) outside CNS . 5 . ECOG 0 , 1 , 2 . 6 . Adequate recovery ( exclude alopecia ) previous surgery , radiation , chemotherapy . 7 . Adequate washout period last therapy ( least 3 week ) . 8 . Life expectancy ≥ 12 week . 9 . Age ≥ 18 year old . 10 . Female patient childbearing potential must negative serum ( betaHCG ) pregnancy test within 14 day start protocol must breastfeed . Men woman childbearing potential ( include men vasectomy woman tubal ligation ) must agree use two effective mean contraception throughout study least 6 month completion protocol . Postmenopausal woman ( define 12 consecutive month amenorrhea , follicle stimulate hormone ( FSH ) postmenopausal range ) , surgically sterile woman ( defined removal uterus ovary ) , require method contraception . 11 . Adequate renal hepatic function : serum creatinine &lt; 1.5 x ULN ; AST ALT &lt; 2.5 x ULN ( &lt; 5 x ULN liver involvement metastasis ) ; serum bilirubin &lt; 1.5 x ULN . 12 . Adequate hematopoietic function : neutrophil ≥ 1.0 x 109/L , platelet ≥ 75 x 109/L . 13 . Provide write consent investigational nature , study design , risk benefit study explain . 14 . Accessible treatment follow . 1 . Symptomatic brain metastasis . 2 . Active cardiovascular disease define New York Heart Association ( NYHA ) class IIIIV categorization . 3 . Intercurrent illness medical condition preclude safe administration plan protocol treatment require followup . 4 . Use investigational anticancer drug within 2 week start study treatment inadequate recovery toxic effect therapy . 5 . Female patient pregnant breastfeeding . 6 . Concurrent treatment anticancer therapy . Bisphosphonates allow long start prior screen ( least 4 week study entry ) . 7 . Known infection HIV . 8 . History malignancy past 5 year . Subjects diseasefree 1 year subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>high eIF4E expression</keyword>
	<keyword>solid tumor cancer</keyword>
</DOC>